BioPharmX Corp fka BPMX

[Whos_Who]

Moving towards a fast track with FDA!

Food and Drug Administration has waived its requirement for a dermal carcinogenicity study for BPX-01, eliminating several years of non-clinical research normally required for FDA review.

"The FDA waiver is important because it shaves years off of our non-clinical research, accelerating our regulatory schedule and eliminating concerns about the added time and costs of our non-clinical development,”